Compare Freeport-McMoRan Inc (FCX) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Immunovant Inc. Common Stock — how do they compare? Freeport-McMoRan Inc trades at $73.22 (market cap $102.16B), while Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B). The key difference: Freeport-McMoRan Inc is far larger — about 16.3× Immunovant Inc. Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.84% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Immunovant Inc. Common Stock for 0 Days on average.
| FCX | IMVT | |
|---|---|---|
Market Cap | $102.16B | $6.25B |
Volume | 9,047,971 | 1,755,411 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $44.96 |
52-Week Low | $38.65 | $17.03 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $108.44B | $5.35B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.87, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $73.27. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $25.92 billion, with net income of $2.20 billion and a net margin of 11.38%. Recent news highlights strong copper demand driven by AI and data center growth, positioning FCX to benefit from favorable market trends.
The outlook for FCX is positive, supported by robust copper demand and expansion projects, but risks include rising production costs and potential regulatory investigations. Analyst sentiment is predominantly bullish, with 61% recommending buy. The stock offers growth potential from commodity tailwinds, though investors should monitor cost pressures and execution of growth initiatives.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
